JP2011527575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527575A5 JP2011527575A5 JP2011517443A JP2011517443A JP2011527575A5 JP 2011527575 A5 JP2011527575 A5 JP 2011527575A5 JP 2011517443 A JP2011517443 A JP 2011517443A JP 2011517443 A JP2011517443 A JP 2011517443A JP 2011527575 A5 JP2011527575 A5 JP 2011527575A5
- Authority
- JP
- Japan
- Prior art keywords
- gene expression
- level
- tumor
- heyl
- cancer tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 24
- 101150019344 Heyl gene Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 102000005650 Notch Receptors Human genes 0.000 claims description 6
- 108010070047 Notch Receptors Proteins 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 208000037841 lung tumor Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 239000013068 control sample Substances 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8012208P | 2008-07-11 | 2008-07-11 | |
| US61/080,122 | 2008-07-11 | ||
| US12/360,790 US7544476B1 (en) | 2008-07-11 | 2009-01-27 | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
| US12/360,790 | 2009-01-27 | ||
| PCT/US2009/045479 WO2010005644A1 (en) | 2008-07-11 | 2009-05-28 | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527575A JP2011527575A (ja) | 2011-11-04 |
| JP2011527575A5 true JP2011527575A5 (enExample) | 2012-07-12 |
Family
ID=40688675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517443A Pending JP2011527575A (ja) | 2008-07-11 | 2009-05-28 | Ｎｏｔｃｈシグナル伝達のインヒビターでの処置に感受性であるがんの同定 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7544476B1 (enExample) |
| EP (1) | EP2313526A4 (enExample) |
| JP (1) | JP2011527575A (enExample) |
| AU (1) | AU2009269081A1 (enExample) |
| CA (1) | CA2730215A1 (enExample) |
| WO (1) | WO2010005644A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007136856A2 (en) * | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor |
| WO2008076960A2 (en) | 2006-12-18 | 2008-06-26 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| DK2935330T3 (da) | 2012-12-19 | 2019-07-22 | Aveo Pharmaceuticals Inc | Anti-notch3-antistoffer |
| EP3448420B1 (en) | 2016-04-29 | 2022-09-14 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibody |
| EP3462349A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047878A1 (en) | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
| CA2600908A1 (en) | 2005-03-04 | 2006-09-08 | The Hospital For Sick Children | Methods for cancer prognosis |
| DK1962895T3 (da) * | 2005-12-16 | 2013-03-04 | Regeneron Pharma | TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST |
| WO2007136856A2 (en) | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor |
-
2009
- 2009-01-27 US US12/360,790 patent/US7544476B1/en not_active Expired - Fee Related
- 2009-05-28 EP EP09794862A patent/EP2313526A4/en not_active Withdrawn
- 2009-05-28 JP JP2011517443A patent/JP2011527575A/ja active Pending
- 2009-05-28 WO PCT/US2009/045479 patent/WO2010005644A1/en not_active Ceased
- 2009-05-28 AU AU2009269081A patent/AU2009269081A1/en not_active Abandoned
- 2009-05-28 CA CA2730215A patent/CA2730215A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonne et al. | Salivary biomarker development using genomic, proteomic and metabolomic approaches | |
| Lohaus et al. | HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) | |
| JP2011527575A5 (enExample) | ||
| Coate et al. | Molecular predictive and prognostic markers in non-small-cell lung cancer | |
| Raimondi et al. | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment | |
| Siegal et al. | Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab | |
| Yang et al. | Gene expression profile and angiogenic markers correlate with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer | |
| JP2015523569A5 (enExample) | ||
| RU2017126701A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
| RU2010123381A (ru) | Способ и композиции для диагностического применения у раковых пациентов | |
| CN103608683A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| JP2013541339A5 (enExample) | ||
| HRP20231525T1 (hr) | Postupci i pripravci za dijagnozu i liječenje raka | |
| Cole-Healy et al. | The relationship between semaphorin 3C and microvessel density in the progression of breast and oral neoplasia | |
| JP2019534321A5 (enExample) | ||
| Verbeke et al. | Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart | |
| JP2015210268A5 (enExample) | ||
| Bertoli et al. | Liquid biopsy in NSCLC: an investigation with multiple clinical implications | |
| JP2009516178A5 (enExample) | ||
| JP2018527886A5 (enExample) | ||
| WO2014028222A1 (en) | Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug | |
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma | |
| JP2013505008A5 (enExample) | ||
| JP2016528914A (ja) | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 | |
| JP2017529852A5 (enExample) |